Ginkgo Bioworks (DNA) Set to Announce Quarterly Earnings on Tuesday

Ginkgo Bioworks (NYSE:DNA) is scheduled to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($2.40) per share for the quarter. Ginkgo Bioworks has set its FY 2024 guidance at EPS.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($3.20) EPS for the quarter, meeting the consensus estimate of ($3.20). The firm had revenue of $56.21 million during the quarter, compared to the consensus estimate of $41.46 million. Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. On average, analysts expect Ginkgo Bioworks to post $-6 EPS for the current fiscal year and $-8 EPS for the next fiscal year.

Ginkgo Bioworks Trading Up 5.3 %

Shares of NYSE:DNA opened at $8.04 on Wednesday. The company has a market capitalization of $446.59 million, a P/E ratio of -0.44 and a beta of 1.09. The company’s 50-day moving average price is $7.53. Ginkgo Bioworks has a 12 month low of $5.26 and a 12 month high of $75.20.

Analysts Set New Price Targets

DNA has been the topic of several research analyst reports. The Goldman Sachs Group reduced their price target on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. TD Cowen boosted their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Finally, BTIG Research boosted their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research report on Friday, August 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.16.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.